For many advanced practitioners, patients with hematologic malignancies may present infrequently due to the rarity of occurrence. The heterogenous presentation and clinical course of these diseases, along with the fast pace of scientific discovery, creates a challenging environment for clinicians to stay up to date on clinical management. This collection of presentations provides advanced practitioners with a comprehensive overview of treatment strategies and best practices for the side-effect management of novel therapies for various hematologic malignancies.

Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Error loading Partial View script (file: ~/Views/MacroPartials/JADPRO CE Faculty.cshtml)
Error loading Partial View script (file: ~/Views/MacroPartials/JADPRO CE Topic Items.cshtml)

These CME/CE/CPE certified activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.